Literature DB >> 20332085

Embryonic lethal abnormal vision-like HuR-dependent mRNA stability regulates post-transcriptional expression of cyclin-dependent kinase inhibitor p27Kip1.

Gudrun Ziegeler1, Jie Ming, Jana C Koseki, Sema Sevinc, Ting Chen, Suleyman Ergun, Xuebin Qin, Bertal H Aktas.   

Abstract

The cyclin-dependent kinase inhibitor p27(Kip1) plays a critical role in regulating entry into and exit from the cell cycle. Post-transcriptional regulation of p27(Kip1) expression is of significant interest. The embryonic lethal abnormal vision (ELAV)-like RNA-binding protein HuR is thought be important for the translation of p27(Kip1), however, different reports attributed diametrically opposite roles to HuR. We report here an alternative mechanism wherein HuR regulates stability of the p27(Kip1) mRNA. Specifically, human and mouse p27(Kip1) mRNAs interact with HuR protein through multiple U-rich elements in both 5' and 3' untranslated regions (UTR). These interactions, which occur in vitro and in vivo, stabilize p27(Kip1) mRNA and play a critical role in its accumulation. Deleting HuR binding sites or knocking down HuR expression destabilizes p27(Kip1) mRNA and reduces its accumulation. We also identified a CT repeat in the 5' UTR of full-length p27(Kip1) mRNA isoforms that interact with a approximately 41-kDa protein and represses p27(Kip1) expression. This CT-rich element and diffuse elements in the 3' UTR regulate post-transcriptional expression of p27(Kip1) at the level of translation. This is the first demonstration that HuR-dependent mRNA stability and HuR-independent mRNA translation plays a critical role in the regulation of post-transcriptional p27(Kip1) expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332085      PMCID: PMC2865301          DOI: 10.1074/jbc.M110.113365

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Living with or without cyclins and cyclin-dependent kinases.

Authors:  Charles J Sherr; James M Roberts
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

2.  The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase.

Authors:  M Brandeis; T Hunt
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

3.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.

Authors:  H Aktas; H Cai; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

Review 5.  Cyclin dependent kinase regulation.

Authors:  E Lees
Journal:  Curr Opin Cell Biol       Date:  1995-12       Impact factor: 8.382

6.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

7.  Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome.

Authors:  C Woenckhaus; S Maile; S Uffmann; M Bansemir; T Dittberner; M Poetsch; J Giebel
Journal:  Histol Histopathol       Date:  2005-04       Impact factor: 2.303

Review 8.  Regulatory networks of the retinoblastoma protein.

Authors:  W H Lee; P L Chen; D J Riley
Journal:  Ann N Y Acad Sci       Date:  1995-03-27       Impact factor: 5.691

9.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

10.  p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes.

Authors:  Arpita Ray; Melissa K James; Stéphane Larochelle; Robert P Fisher; Stacy W Blain
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 5.069

View more
  14 in total

1.  Development of 1-((1,4-trans)-4-Aryloxycyclohexyl)-3-arylurea Activators of Heme-Regulated Inhibitor as Selective Activators of the Eukaryotic Initiation Factor 2 Alpha (eIF2α) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response.

Authors:  Revital Yefidoff-Freedman; Jing Fan; Lu Yan; Qingwen Zhang; Guillermo Rodrigo Reis Dos Santos; Sandeep Rana; Jacob I Contreras; Rupam Sahoo; Debin Wan; Jun Young; Karina Luiza Dias Teixeira; Christophe Morisseau; Jose Halperin; Bruce Hammock; Amarnath Natarajan; Peimin Wang; Michael Chorev; Bertal H Aktas
Journal:  J Med Chem       Date:  2017-06-19       Impact factor: 7.446

2.  Structure-activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein-protein interaction inhibitors.

Authors:  Khuloud Takrouri; Ting Chen; Evangelos Papadopoulos; Rupam Sahoo; Eihab Kabha; Han Chen; Sonia Cantel; Gerhard Wagner; Jose A Halperin; Bertal H Aktas; Michael Chorev
Journal:  Eur J Med Chem       Date:  2014-03-13       Impact factor: 6.514

3.  In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.

Authors:  Séverine Denoyelle; Ting Chen; Limo Chen; Yibo Wang; Edvin Klosi; José A Halperin; Bertal H Aktas; Michael Chorev
Journal:  Bioorg Med Chem Lett       Date:  2011-11-16       Impact factor: 2.823

4.  Conditional knockout of the RNA-binding protein HuR in CD4⁺ T cells reveals a gene dosage effect on cytokine production.

Authors:  Matthew M Gubin; Patsharaporn Techasintana; Joseph D Magee; Garrett M Dahm; Robert Calaluce; Jennifer L Martindale; Maryln S Whitney; Craig L Franklin; Cindy Besch-Williford; John W Hollingsworth; Kotb Abdelmohsen; Myriam Gorospe; Ulus Atasoy
Journal:  Mol Med       Date:  2014-03-20       Impact factor: 6.354

5.  Explorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinase.

Authors:  Ting Chen; Khuloud Takrouri; Sung Hee-Hwang; Sandeep Rana; Revital Yefidoff-Freedman; Jose Halperin; Amarnath Natarajan; Christophe Morisseau; Bruce Hammock; Michael Chorev; Bertal H Aktas
Journal:  J Med Chem       Date:  2013-11-27       Impact factor: 7.446

6.  Dual activators of protein kinase R (PKR) and protein kinase R-like kinase PERK identify common and divergent catalytic targets.

Authors:  Huijun Bai; Ting Chen; Jie Ming; Hong Sun; Peng Cao; Dahlene N Fusco; Raymond T Chung; Michael Chorev; Qi Jin; Bertal H Aktas
Journal:  Chembiochem       Date:  2013-06-19       Impact factor: 3.164

7.  Tumor suppression by small molecule inhibitors of translation initiation.

Authors:  Limo Chen; Bertal H Aktas; Yibo Wang; Xiaoying He; Rupam Sahoo; Nancy Zhang; Severine Denoyelle; Eihab Kabha; Hongwei Yang; Revital Yefidoff Freedman; Jeffrey G Supko; Michael Chorev; Gerhard Wagner; Jose A Halperin
Journal:  Oncotarget       Date:  2012-08

8.  Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target.

Authors:  Ting Chen; Duygu Ozel; Yuan Qiao; Fred Harbinski; Limo Chen; Séverine Denoyelle; Xiaoying He; Nela Zvereva; Jeffrey G Supko; Michael Chorev; Jose A Halperin; Bertal H Aktas
Journal:  Nat Chem Biol       Date:  2011-07-17       Impact factor: 15.040

9.  Depletion of eIF2·GTP·Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.

Authors:  Bertal H Aktas; Paula Bordelois; Selen Peker; Sophia Merajver; Jose A Halperin
Journal:  Oncotarget       Date:  2015-03-30

10.  Small-Molecule targeting of translation initiation for cancer therapy.

Authors:  Bertal H Aktas; Yuan Qiao; Esra Ozdelen; Roland Schubert; Sema Sevinc; Fred Harbinski; Luciano Grubissich; Samuel Singer; Jose A Halperin
Journal:  Oncotarget       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.